Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
ADTRAN Holdings, Inc. (ADTN) - free report >>
AZZ Inc. (AZZ) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ADTRAN Holdings, Inc. (ADTN) - free report >>
AZZ Inc. (AZZ) - free report >>
Image: Bigstock
New Strong Sell Stocks for July 10th
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
ADTRAN, Inc. (ADTN - Free Report) is a provider of networking and communications equipment. The Zacks Consensus Estimate for its current year earnings has been revised 23.8% downward over the last 60 days.
Alaska Air Group, Inc. (ALK - Free Report) is a provider of passengers and cargo air transportation services. The Zacks Consensus Estimate for its current year earnings has been revised 9% downward over the last 60 days.
AZZ Inc. (AZZ - Free Report) is a provider of galvanizing, metal coating and welding services. The Zacks Consensus Estimate for its current year earnings has been revised 18.6% downward over the last 60 days.
AmeriGas Partners, L.P. is a distributor of propane and related equipment. The Zacks Consensus Estimate for its current year earnings has been revised 2% downward over the last 60 days.
Aptose Biosciences Inc. (APTO - Free Report) is the owner and operator of a clinical-stage biotechnology company. The Zacks Consensus Estimate for its current year earnings has been revised 22.2% downward over the last 30 days.
View the entire Zacks Rank #5 List.